Clinical Trial Update: Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating FOLFIRI plus Durvalumab versus FOLFIRI plus Durvalumab and Tremelimumab as second-line treatment for advanced gastric or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Durvalumab (durvalumab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Federation Francophone de Cancerologie Digestive | Conditions: Gastric Adenocarcinoma, Gastric Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING